FACTORS AFFECTING ANTIRETROVIRAL TREATMENT ENTRANCE, ADHERENCE  AND RETENTION AMONG HIV PATIENTS IN NIGERIA AND UGANDA by Ananaba, Nnenna
The Texas Medical Center Library 
DigitalCommons@TMC 
UT School of Public Health Dissertations (Open 
Access) School of Public Health 
Spring 12-2019 
FACTORS AFFECTING ANTIRETROVIRAL TREATMENT 
ENTRANCE, ADHERENCE AND RETENTION AMONG HIV 
PATIENTS IN NIGERIA AND UGANDA 
Nnenna Ananaba 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/uthsph_dissertsopen 
 Part of the Community Psychology Commons, Health Psychology Commons, and the Public Health 
Commons 

FACTORS AFFECTING ANTIRETROVIRAL TREATMENT ENTRANCE, ADHERENCE AND 
RETENTION AMONG HIV PATIENTS IN NIGERIA AND UGANDA 
 
 
by 
 
NNENNA ANANABA, BSc, MPH 
 
 
APPROVED: 
 
 
 
CASEY DURAND, PhD  
ACADEMIC ADVISOR/COMMITTEE CHAIR  
 
 
LU-YU HWANG, MD 
COMMITTEE MEMBER  
 
 
SHERYL MCCURDY, PhD 
COMMITTEE MEMBER  
 
 
DEAN, THE UNIVERSITY OF TEXAS SCHOOL 
OF PUBLIC HEALTH 
  
ii 
 
Copyright 
By 
Ananaba, Nnenna Ogadinma, BSc, MPH, DrPH 
2019 
  
iii 
 
DEDICATION 
To Uchechukwu, Joshua and Daniel Okite 
  
iv 
 
  
v 
 
 FACTORS AFFECTING ANTIRETROVIRAL TREATMENT ENTRANCE, ADHERENCE 
AND RETENTION AMONG HIV PATIENTS IN NIGERIA AND UGANDA  
 
 
 
 
 
NNENNA ANANABA 
MPH, Loma Linda University School of Public Health, 2011 
BSc, University of Ibadan, 2007 
  
 
Presented to the Faculty of The University of Texas 
Health Science Center at Houston  
School of Public Health 
in Partial Fulfillment of 
the Requirements for the 
Degree of 
 
 
DOCTOR OF PUBLIC HEALTH 
 
 
 
 
THE UNIVERSITY OF TEXAS 
HEALTH SCIENCE CENTER 
AT HOUSTON  
SCHOOL OF PUBLIC HEALTH 
Houston, Texas 
December 2019 
  
vi 
 
ACKNOWLEDGEMENTS 
I would like to express my gratitude to my Advisor and Committee Chair, Dr. Casey 
Durand for walking with me through this journey. Your insightful thoughts, patience and 
willingness to give of your time helped me stay on track and complete this research. I also want 
to thank my committee members Dr. Lu-Yu Hwang, Dr. Sheryl McCurdy and Dr. E. James 
Essien for your support and valuable contributions in shaping, executing and presenting this 
research work. Thank you all for insisting on the best work! 
My deepest appreciation goes to my husband, Uchechukwu Okite and my children, 
Joshua and Daniel. Thank you for all the sacrifices, thank you for all the prayers, thank you for 
your patience and encouraging words- I was never alone. To the world’s best parents, Chief 
Emeka Ananaba and Lolo Oduagu Ananaba- words are not enough, this one is for you! To my 
amazing siblings and their families, Ochiagha, Nnenna, Eva and Eli; Ugochukwu, Muna and 
Uma; Ugwunwanyi; Ogbugo; Amaechi and Anita- thank you for babysitting, thank you for 
saying a prayer, thank you for believing in me- we did it! 
Finally, I bow my knees in worship to a faithful God and Father. You held my hand all 
the way. I am in awe of You! 
 
 
 
  
vii 
 
FACTORS AFFECTING ANTIRETROVIRAL TREATMENT ENTRANCE, ADHERENCE 
AND RETENTION AMONG HIV PATIENTS IN NIGERIA AND UGANDA 
 
NNENNA ANANABA, BSc, MPH, DRPH 
The University of Texas 
School of Public Health, 2019 
 
Dissertation Chair: Casey Durand, PhD 
 
Summary: 
 
Introduction: The maximum benefits of antiretroviral therapy (ART) are achieved when HIV 
patients follow through the HIV Care Continuum. Understanding the factors that impact the Care 
Continuum are key in minimizing late ART uptake while increasing treatment retention and 
adherence in sub-Saharan Africa.  
 
Objectives: To explore factors that impact the various phases of the HIV Care Continuum, we 
review trends in median CD4 cells count and presentation with HIV advanced disease stage 
between 2013 and 2017. We also examined treatment retention rates and the impact of food 
security on ART adherence. 
 
Methods: Two datasets were reviewed. One dataset consists of data abstracted from 1100 HIV 
clinic records of adults aged 15 who initiated ART between 2013 and 2017 at a comprehensive 
clinic in Nigeria. The other dataset was a cross-sectional study conducted among HIV patients 
aged 18 years in Uganda.  
 
Data analysis: We used Chi square tests to compare baseline median CD4 cell counts and HIV 
advanced disease stage among males and females initiating ART between 2013 and 2017. 
Logistic regression was used to determine retention rates over time as well as ART adherence. 
All data was analyzed using STATA version 15. 
 
 Results: The overall median CD4 cell count was 243.5 cells/l. Men had a downward median 
CD4 cell count trend and presented late to treatment compared to females. Patients aged 36 and 
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those with TB also presented with advanced HIV disease stage at ART initiation. Nigeria 
National HIV policy changes had no impact in late presentation to ART uptake. ART treatment 
retention was 71.39%, 79.50%, 74.01% and 62.67% at 6, 12, 24 and 36 months respectively. 
CD4 cell count <100 was inversely predictive of retention (AOR 0.55; 95% CI, 0.37-0.82) while 
female gender (AOR, 2.00; 95% CI, 1.02 – 3.89), older age (AOR, 1.88; 95% CI, 1.01-3.51), TB 
at start (AOR, 2.21; 95% CI, 1.02-4.75). and CD4 cell count 100-199 (AOR, 2.54; 95% CI, 1.04-
6.20) were significantly associated with retention. Overall food security level in Uganda was 
65.5%. HIV positive males reported higher food security levels compared to females (77.60% vs 
61.90). Food security (AOR, 1.76; 95% CI, 1.03-3.01), income (AOR 2.69; 95% CI, 1.14-6.34) 
and nutrition counseling (AOR, 1.99; 95% CI, 1.12-3.54) were associated with good adherence.  
 
Conclusion: Various factors contribute gaps in the HIV Care Continuum and foster existing 
gender disparities in HIV care outcomes. Interventions targeting men for early ART uptake and 
treatment retention are needed. Promoting food security and treatment support programs may be 
effective in advancing HIV care in the sub-Saharan Africa. Further research is needed to 
examine the long -term impact of HIV policy and program changes. 
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BACKGROUND 
 
The Human Immunodeficiency Virus (HIV) continues to remain a key public health issue in the 
world (1,2). Since HIV was identified in the 1980s, an estimated 74.9 million people have become 
infected with the virus, and 32 million people have been reported to have died of HIV-related 
illnesses (2). In 2018 alone, records show about 1.7 million new HIV infections, 770,000 HIV-
related deaths, and approximately 37.9 million people living with HIV across the globe (1). 
Notwithstanding improved HIV funding and programs, only 62% of the 29.9 million people who 
know their status were receiving antiretroviral treatment (ART) and only about  47% were virally 
suppressed in 2018 (1,2). In addition, an estimated 8.1million of people infected by HIV did not 
know their status by the end of 2018 (2). 
 
At the same time, the global epidemiology of HIV has changed remarkably due to increased access 
to ART(3). Increased global efforts have ensured improved access to ART, particularly in 
resource-poor countries since early-mid 2000s (4,5). In 2018, the World Health Organization 
estimated 64% of the people living with HIV in Africa were receiving ART (1).  Access to ART 
has been shown to contribute to reduced HIV-related deaths from 1.4 million in 2000 to less than 
one million in 2018 (5). Besides, reports of reduced new HIV infections have been associated with 
access to ART (3–5). The need to ensure a continuum of care for HIV patients cannot be 
overemphasized.  Yet, treatment dropout and mortality of HIV patients starting ART in resource-
poor settings have been shown to be considerably higher than those starting ART in developed 
countries (6). A review article estimated the treatment dropout rate of 20% after the first year on 
ART (7)  while mortality rate ranged from 8 to 26% among HIV patients within one year of starting 
ART in sub-Saharan Africa (6,8).  These high rates are suspected to be linked to various factors 
such as initial patient clinical characteristics that negatively impact early ART treatment entrance, 
adherence and retention in the sub-Saharan Africa (9–12). While initial patient clinical 
characteristics are intrinsic, socio-economic factors such as food insecurity level, social support 
and the effects of HIV status disclosure may also deter patients from seeking ART treatment early 
and impact ART adherence and retention (13,14). Moreover, some studies report that medication 
related factors such as drug side effects may interact with ART treatment retention as HIV patients 
2 
 
report drug side effects as a barrier to taking their medication (13–15). In contrast, very few studies 
have been conducted to examine the multiple interactions between structural factors such as care 
entry point, social factors such as enrollment in treatment support groups and economic factors 
such as food insecurity levels with HIV identification, uptake, adherence and retention in the sub-
Saharan Africa (16) even as many other factors still remain unknown or inconclusive. 
 
 
HIV in Sub-Saharan Africa 
 
The HIV epidemic is known to have started in the late 1970s and early 1980s in the sub-Saharan 
Africa. The virus in this region has been found to present with two distinct virus types: HIV-1 and 
HIV- 2. The HIV-1 strain is argued to have emerged in West Central Africa in the early 20th century 
and diversified in the Congo River basin, where the highest viral diversity occurred (17). The HIV-
1 strain presents in four groups (M, N, O, P) and group M, which, is reported to present with 9 
subtypes (A-D, F-H, J, K) is responsible for the global pandemic (17,18). The HIV-2 is mostly 
found in the West African region and it is not easily transmitted (18).  
 
The main mode of HIV transmission in the sub-Saharan is via heterosexual intercourse (5,18). The 
risk of transmission is heightened by multiple sexual partners and coexisting sexually transmitted 
infections such as herpes simplex type 2 (5). A large proportion of the new HIV infection in this 
region may be attributable to long-term heterosexual relationships and sexual behaviors whereby 
young women have sex with older men (5,18). This pattern may be one of the reasons why the 
sub-Saharan is the only region in the world with HIV infection rates higher among women than 
men (18). 
 
Overall, the sub-Saharan African has been worst hit by the HIV epidemic (18). Even though only 
10% of the world’s population lives in sub-Saharan Africa, The adult HIV prevalence rate for East 
African countries in between 8-10%, West Africa about 3% and South Africa about 20% (18). 
Since HIV is the fifth leading cause of morbidity and mortality (3) and the vast majority (an 
estimated 25.7 million) of people living with HIV reside in low- and middle- income countries 
which includes the sub-Saharan Africa (3,5,18), there is a need to continue studying the factors 
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affecting ART treatment entrance, adherence and retention in these countries. This is imperative 
given that an estimated 70% of all HIV infected children and adults live in sub-Saharan Africa and 
achieving global targets towards ending the HIV epidemic is largely tied to the progress made in 
combating HIV in Africa (2,18).  
 
HIV in Nigeria 
 
Nigeria is the most populated country in the sub-Saharan Africa. Her first case of HIV was 
recorded in 1985 (19). The HIV-1 Group M subtype A and G are reported as the dominant strains 
of HIV in Nigeria (20). However, current research shows emerging dominant recombinant strains 
CRF02_AG in the southern part of the country(21). The southern part of Nigeria has also continued 
to show higher incidence rates of HIV which require further studies to understand the current 
trends (21).  
 
Even though the government set up a National Expert Advisory Committee on AIDS and requested 
assistance from the WHO, no serious efforts to combat the virus was recorded until the return on 
democracy in 1999 (19).  At that time, a national surveillance showed a HIV prevalence of 5.8%, 
which then continued to decrease to 1.5% in 2018 probably due to the increased access to ARTs. 
However, the fact that 3.1 million people still live with HIV in Nigeria in 2017, makes her the 
second largest HIV epidemic in the world (2). 
 
Like most other African countries, heterosexual intercourse has been found to contribute greatly 
to HIV transmission in Nigeria and it accounted for over 80% of the infections in the nation (19). 
Other drivers of HIV transmission include: mother- to- child transmission, sex workers, men who 
have sex with men (MSM) and injection users (19,22) exacerbated by low condom usage, punitive 
laws against sex workers and MSM, gender inequalities and high sexual networking (19). 
Moreover, the government’s initial slow response to tackling HIV may have added to the far-
reaching adverse effects of the virus in Nigeria (19). 
 
On the other hand, since the early 2000s, Nigeria has scaled-up HIV prevention services through 
concerted efforts from local and international organizations. More HIV programs and clinics have 
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been established to increase HIV awareness as well as access to ARTs (19). Yet, Nigeria continues 
to face challenges in attaining national and international benchmarks regarding early HIV 
treatment uptake and retention. For example, in 2018, only 53% of the adult HIV patients were 
reported to be receiving ART(1,2) and only 67% of the population knew their HIV status (2,23). 
Furthermore, only 44% of the pregnant women living with HIV received ART for prevention of 
mother-to-child transmission (PMTCT) in 2018 (23). While these may be attributed to weak health 
systems in the country, it also suggests there are barriers for people to access and/or stay in ART 
treatment (23) and these factors could have been further entrenched through other economic, 
structural and cultural barriers that affect early ART treatment uptake, treatment adherence and 
retention (23).  Therefore, exploring the interaction of these factors would provide insights on how 
to ensure early detection of HIV, early ART treatment uptake and treatment adherence and 
retention.  
 
HIV in Uganda 
 
Uganda is another country in the sub-Saharan Africa with a high prevalence of HIV. The first case 
of HIV in Uganda was reported in 1982. The HIV-1 Group M subtype A and D are reported as the 
dominant strains of HIV in Uganda (17,24). Current research suggests the existence of other strains 
and recombinant strains in Uganda as well (25). Uganda recorded high rates of HIV infection in 
the 1980s and early 1990s with national prevalence of about 30% in 1989 (26).  This led to a strong 
response by the government in the adoption of a Multi-Sectorial AIDS Control Approach as well 
as the establishment of the Uganda AIDS Commission in 1992 (26). As a result, by the early 2000s 
Uganda had implemented safer birth practices and offered about 41,000 women PMTCT services 
(26). By 2018, Uganda had reached 97% of HIV positive pregnant women with PMTCT services 
(27). Uganda is also known as the first country in the sub-Saharan to offer HIV voluntary 
counseling and testing (HCT) (26). HIV prevention programs in Uganda also aimed at increasing 
HIV awareness and testing, and condom use and treatment uptake which contributed to decreased 
adult HIV prevalence from 14% in the early 1990s to about 8% in mid-2000 (18). Currently, the 
adult HIV prevalence in Uganda is 5.7% (2). 
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However, despite the gains made by the government and its partners to combat HIV, Uganda, like 
most sub-Saharan countries, still faces various challenges in addressing the HIV burden. Some of 
the leading barriers include gender inequality, social stigma, and punitive laws against key 
populations. Additionally, unlike that in Nigeria, extreme economic factors leading to increased 
poverty has also increased food insecurity in the region (28,29) and studies show food insecurity 
is an emerging factor associated with ART adherence among HIV patients (10,30–32).  There is 
also a dispute on the level of impact that gender differences among HIV patients may have on food 
insecurity and ultimately on ART treatment adherence in Uganda (28). Therefore, it is also 
important to explore the association between food insecurity and ART adherence in Uganda who 
is known to have established food-related gender differences (33,34).  
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AIMS 
In order to examine the factors that interact with ART treatment entrance, adherence and retention, 
this study aims to: 
1. Examine the trends of median CD4 cell count and the impact of HIV policy change on 
ART treatment presentation at a Nigerian clinic from October 2013 to December 2017. 
The hypotheses were as follows: 
 
a. There is an upward trend in median CD4 cell count at baseline among females 
compared to males  
b. The odds of presenting with advanced HIV disease stage are higher among males 
compared to females 
 
2. Determine the association of patient baseline characteristics with treatment retention at 6, 
12, 24 & 36 months among HIV patients who initiated ART treatment between October 
2013 and December 2017 at a Nigerian clinic. The hypotheses are as follows: 
 
a. The odds of treatment retention at 6, 12, 24 and 36 months post- ART initiations 
are lower among patients who enter HIV care with lower CD4 cell count compared 
to those who enter with higher CD4 cell counts. 
 
b. The odds of treatment retention at 6, 12, 24 and 36 months post- ART initiations 
are lower among patients who enter HIV care with a positive TB status compared 
to those who enter with a negative TB status. 
 
3. Determine the relationship between household food insecurity and ART treatment 
adherence among HIV patients in two Ugandan clinics and determine whether this 
interaction differs by gender. The hypotheses are as follows: 
 
a. The odds of good ART adherence are higher among patients who are food secure 
as compared food insecure patients. 
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b. The odds of good ART adherence are higher among  patients who received 
treatment support services as compared to those who did not receive treatment 
support services. 
 
 
METHODS 
 
Data Sources 
This study involved the use of de-identified data of HIV patients aged 15 and above from two 
different sub-Saharan countries with different HIV strains and responses to the HIV epidemic. The 
first data source was de-identified data abstracted from the clinic records of a retrospective cohort 
of HIV patients enrolled at a comprehensive urban hospital in Nigeria. The second data source was 
de-identified secondary data from a cross-sectional study involving HIV patients receiving ART 
at two level 3 health care centers in rural and semi-urban communities in Uganda. 
 
Nigerian Data: 
Patient records showing ART treatment enrollment between October 2013 and December 2017 
(study period) were identified and marked for data abstraction. Trained data officers and the HIV 
clinic officers performed the data abstraction. Data abstraction was done using an excel 
spreadsheet developed for this study to retrieve variables of interest from patient clinic and follow-
up records. Since medical record information are routinely and prospectively collected by health 
care providers, recall bias was reduced. The HIV clinic coordinator was asked to assist with data 
quality checks by randomly reviewing data entry. De-identified data was received electronically. 
Data was cleaned and transferred to STATA for analysis. 
 
Ugandan Data: 
De-identified patient records from a cross-sectional study involving HIV patients receiving ART 
at two level 3 health care centers in rural and semi-urban communities in Uganda was used. Data 
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was collected on a given data collection day using a one-time structured survey (with ART 
adherence and food security level questions) from consenting patients who attended the health 
center between November 2017 and February 2018. Electronic dataset with variables of interest 
was transferred on request. Data was cleaned and transferred to STATA for analysis. 
 
PUBLIC HEALTH SIGNIFICANCE  
 
The expansion of ART coverage has greatly improved survival among people living with HIV (5). 
Access to ART is noted as the main contributing factor in the estimated 28% decline in HIV-
related deaths from 2006 to 2012 (5). However, in the sub-Saharan Africa, only an estimated 60% 
of people living with HIV are currently receiving ART (5). 
 
Through exploring the relationship between HIV care entry points and ART treatment uptake, this 
study will inform HIV program planners of ways to increase opportunities for early HIV detection 
and early treatment commencement to promote retention. Identifying new strategies while 
addressing gender and age differences could also guide HIV program plans to increase timely 
gender- and age- focused HIV detection and treatment enrollment. Furthermore, this study will 
inform partnerships between health care providers to increase HIV care entry points thus 
increasing early treatment uptake and retention. This study will also contribute knowledge to the 
benefit of a more comprehensive HIV care approach, which includes social support from treatment 
support groups and patient family.  
 
Besides, the sustainability of previous successes in HIV treatment adherence and retention is at 
stake as the effects of food insecurity persists due to widespread poverty in the sub-Saharan Africa 
(35,36), as food insecurity can compromise the long-term benefits of ART due to its interaction 
with treatment adherence. Assessing the relationship between food insecurity levels and ART 
adherence will then inform policy makers on whether there is need to incorporate regular food 
security assessment checks as part of the routine HIV care for sustained HIV program success 
across similar settings in the sub-Saharan. It will also enable health providers to identify HIV 
patients who may need referrals to food assistance programs as this could ultimately help improve 
ART adherence and treatment retention. 
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Additionally, understanding the role of gender in modifying food insecurity and ART adherence 
as well as treatment retention may serve to strengthen existing programs for sustainability. 
Identifying a gender difference, will support the development of interventions will be more 
effective in achieving program goals, improving patient health outcomes while addressing gender 
differences. Study results may also provide a basis to identify patients who are most at risk of ART 
non-adherence and treatment dropout so as to provide targeted care for long-term treatment 
adherence and retention.  
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JOURNAL ARTICLE 1 
Trends and Correlates of Advanced HIV Disease Stage at Antiretroviral Therapy 
Initiation: The impact of changes in HIV treatment guidelines in Nigeria. 
 
Journal: PLoS ONE 
 
Abstract: 
 
Background: HIV patients starting antiretroviral treatment (ART) with advanced disease stage 
minimize the effectiveness of ARTs, jeopardize their health outcomes and contribute to new HIV 
infections. We examined the trends in treatment presentation with advanced disease stage and 
reviewed the impact of changes in national HIV policy on treatment uptake.  
Methods: A retrospective cohort study of data abstracted from 1050 HIV clinic records of adults 
aged 15 who initiated ART between 2013 and 2017 at a comprehensive clinic in Nigeria. 
Advanced HIV disease at ART initiation was defined as having a CD4 cell count of less than 
100cells/l or a WHO clinical stage 4 at start of ART. All data was analyzed using STATA version 
15.  
Results: The study population was 33.05% males and the median age was 34 years (inter quartile 
range [IQR], 29-40). Males had a plunging median CD4 cell count compared to females over time 
(219 cells/l in 2013 to 159cells/l in 2017 vs 262.5 cells/l in 2013 to 274 cells/l in 2017). 
Males also continued to present late to ART treatment uptake with advanced HIV disease stage 
compared to females (19.23 % vs 16.13% in 2013 and 44.83% vs 22.64% in 2017). In multivariate 
analysis, year of ART, age and documented TB at baseline were significantly associated with late 
presentation. Patients who had TB at baseline, enrolled in 2016 and 2017 and aged 36 showed 
higher odds of presenting with advanced HIV disease stage at ART initiation. There was no 
significant association between the 2015 National HIV treat all policy piloted in our study region 
and late presentation to ART uptake.  
Conclusion: Late presentation for ART uptake is still a major challenge in Nigeria. There is a 
widening gap in ART treatment uptake among males compared to their female counterparts. 
Interventions targeting men for early ART uptake are needed. Further research is needed to 
examine the long -term impact of HIV policy and program changes. 
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Keywords: Late ART presentation, ART treatment uptake, advanced disease stage, median CD4 
cell count, TB, Gender, Resource-limited setting, HIV policy changes. 
 
 
INTRODUCTION 
 
With the significant increase in funding for Human Immunodeficiency Virus (HIV) prevention, 
care, treatment and support programs worldwide, more HIV infected individuals have been able 
to receive the antiretroviral therapy (ART) (1,2). By the time the ‘3 by 5’ initiative was launched 
in 2003, only 400,000 people were estimated to be receiving ART worldwide (3) but by the end 
of 2018, an estimated 23.3 million people were reported to be receiving ART worldwide (4). The 
sub-Saharan Africa has recorded the most tremendous increase (about 40%) in the number of 
people receiving ART with about 16.3 million people in 2018 from about 5 million people in 2010 
(5).  
 
However, the persistent problem of late ART initiation with advanced HIV disease stage in the 
sub-Saharan Africa diminishes the full potential of HIV scale-up in the region (6,7). Also, the high 
HIV-related mortality rates reported in sub-Saharan Africa have been associated with low CD4 
cell counts at ART initiation (7). Data show trends in median CD4 cell count remained below 
200cells/l in most low- and middle- income countries as at 2010 (2). This trend suggests the need 
to increase efforts towards early ART initiation, which serves to increase immune response and 
improve patient health outcomes.  
 
Conversely, individual country HIV treatment guidelines are an important reference point for ART 
initiation. In 2015, the World Health Organization (WHO) proposed the ‘test and treat all’ HIV 
treatment guidelines which seeks to increase ART initiation and prevent HIV transmission (9). In 
2015, Nigeria began a pilot test of the ‘test and treat all’ in select local government areas before 
fully implementing the guidelines across the nation in December 2016 (9). Even though Nigeria 
has continued to scale up ART provision, there is only an estimated 53% ART coverage of the 1.9 
million people currently living with HIV in the country (10,11). Furthermore, Nigeria 2018 
country data show that of the 1.9 million people living with HIV in the country, about 1 million 
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are women aged 15 and above and only an estimated 68% of those women were reported to be 
receiving ART (9). Nigeria HIV data continues to show a disproportionate distribution of the HIV 
burden across age, gender and geographic region. Understanding how these factors contribute to 
advanced disease stage at ART initiation is vital to inform HIV program designs and support 
targeted interventions. 
 
ART initiation with advanced disease stage results in a delay in CD4 cell count response; adding 
a considerable burden and cost to care, contributes missed opportunities to HIV prevention thereby 
increasing new infections and significant early mortality (2,6,8). Therefore, it is imperative that 
trends in ART treatment presentation be reviewed over time and the impact of policies aimed at 
driving early ART treatment be reviewed for effectiveness. Consequently, the objectives of this 
study were to assess the trends in median CD4 cell count and determine the extent of advanced 
disease stage at ART initiation across gender from 2013 to 2017 at a comprehensive hospital in 
Nigeria that participated in the pilot test of the ‘test and treat all’ policy.   
 
 METHODS 
We conducted a retrospective cohort analysis of HIV infected individuals receiving ART treatment 
at a HIV clinic in a comprehensive hospital in south-south Nigeria from January 2013 to December 
2017.  
 
Data Source 
Patient information routinely collected at HIV treatment enrollment and during subsequent clinic 
visit was documented by clinic staff on standard forms used nationally. Trained data clerks 
manually abstracted 1,050 adult (aged ≥15 years) medical records from the hospital HIV clinic 
records and entered then into an electronic database. Data quality assessments were carried out 
every month to assess for accuracy and completeness until data collection was completed. Data 
was de-identified for analysis. 
 
Definitions and Outcomes 
Advanced HIV disease at ART initiation was defined as having a CD4 cell count of less than 
100cells/l or a WHO clinical stage 4 at start of ART. 
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Data Analysis 
We examined characteristics of all study eligible patients initiating ART at the clinic. We then 
assessed the proportion of patients with advanced HIV disease at ART initiation. We also 
examined trends over time in proportion with advanced disease stage at ART initiation as well as 
median CD4 cell count at ART initiation from 2013 to 2017 by gender. Bivariate analysis of 
advanced disease stage and each of the covariate was assessed and reported. All covariates were 
added to a multivariable model to determine any significant correlates to advanced disease stage. 
We adjusted for age and gender. Odds ratios, adjusted odds ratios, 95% confidence interval and a 
p value was calculated. Significance was set from a p value of < 0.05.  Missing data were assumed 
as missing at random and were not included in the analysis. All statistical analysis was performed 
using Stata 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: 
StataCorp LLC).  
 
Ethical Consideration 
IRB approval was obtained from the research approval committee of the study clinic, and The 
University of Texas Health Science Center at Houston. 
 
RESULTS 
Characteristics of patients initiating ART 
Characteristics of 1050 adults aged 15 and above who initiated ART between January 2013 and 
December 2017 are presented in Table 1. At ART initiation, about two-thirds were women. The 
median age was 34 years (inter quartile range [IQR], 29-40) and 35% of the patients were enrolled 
in 2015. 
 
Clinical and Immunological Characteristics at ART initiation 
 Of all the men who initiated ART, 45% of them presented with CD4 cell counts lower than 200 
cells/l with a median of 229.5 cells/l (Figure 1). Of the men whose WHO clinical stage was 
reported, 35% of them presented with disease stage III and IV. Both male (26%) and female (22%) 
patients presented with advanced disease stage. Female patients had a slightly higher record of 
documented tuberculosis compared to males (10% versus 9%).  
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Trend in Median CD4 cell count and Proportion initiating ART with Advance Disease Stage over 
time 
There was an undulating pattern in the median CD4 cell count of patients initiating ART in our 
study over time (Figure 1). The overall median CD4 cell count decreased between 2013 and 2014 
from 255cells/l to 234cells/l. It peaked in 2015 at 278cells/l and dropped in 2016 (233 cells/l). 
However, in 2017, the overall median CD4 cell count began to increase again.  The median CD4 
cell count for women showed the same pattern as the overall median CD4 cell count but the median 
CD4 cell count for men continued to decrease from 2015 (260 cells/l) to 2017 (159 cells/l). The 
median CD4 cell count for men was lower than the median CD4 cell count for women through the 
study years except in 2014 (Figure 1). 
 
Nearly 25% of all patients presented with advanced HIV disease stage from 2013 to 2017. Women 
presenting with advanced disease stage was highest in 2016 (31.3%) while men presenting with 
advanced disease stage was highest in 2017 (44.8%) (Figure 2). There was no consistent trend for 
presenting with advanced disease stage across gender, however, the year of ART initiation was 
significantly associated with advanced disease stage for all patients (P= 0.02) but not significantly 
associated by the changes in the national HIV guideline to ‘test and treat all’ (Table 2). 
 
Factors associated with Presenting with Advanced HIV Disease at ART initiation  
In a multivariate model (Table 2), higher odds of initiating ART at advanced HIV disease were 
observed among patients aged 36-45 years and 46+ years compared with those aged 15-25 years 
(adjusted odds ratio [AOR], 1.8; 95% CI, 1.01-3.23; AOR, 2.10; 95% CI, 1.10-3.99, respectively), 
(b) patients who initiated ART in 2016 compared to those who initiated ART in 2013 (AOR, 2.06; 
95% CI, 1.08-3.91), (c) patients who had documented tuberculosis (TB) at ART initiation 
compared to those who did not have a documented TB case (AOR, 1.79; 95% CI, 1.09-2.92).  
 
DISCUSSION 
Our study observed substantial increase in the proportion of patients presenting with advanced 
HIV disease at ART between 2013 and 2017 (from 17.05% to 30.49%). This increase was more 
significant among male patients compared to females (from 19.23% to 44.83% versus 16.13% to 
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22.64%). Patients aged 36-45 years as well as those aged 46 years and above were also more likely 
to present with advanced HIV disease stage at ART initiation. This finding is consistent with 
previous literature suggesting that older HIV positive males are still more likely to present late to 
ART treatment compared to women in sub-Saharan Africa (1,8, 12,13). Furthermore, the health 
seeking behaviors of women and the expansion of HIV testing for pregnant women during 
antenatal care through prevention of mother to child treatment (PMTCT) programs in sub-Saharan 
Africa, may be some of the reasons why women tend to initiate ART earlier than men (2,14). 
PMTCT programs have been shown to contribute to earlier diagnosis and treatment uptake among 
asymptomatic reproductive aged women (14–16). The importance of early initiation to ART 
treatment in order to maximize the benefits of ART has been established (17,18). In particular, 
early uptake of ART is key to deterring the onset of opportunistic infections (OIs) and Acquired 
Imunne Deficiency Syndrome (AIDS), reducing HIV transmission and early mortality (1,18). This 
therefore signifies the need for intensified and targeted efforts aimed at increasing earlier diagnosis 
and treatment uptake for HIV positive males.  
 
A distinct direction was not observed for the among all patients initiating ART across the study 
period. Changes in national HIV treatment guidelines, environmental, program and individual 
factors may have contributed to the observed undulating patterns. This finding is comparable with 
a meta-analysis of median CD4 cell count at ART initiation in sub-Saharan Africa that did not find 
any significant change in the trend of CD4 count at ART initiation between 2002-2013 (19). In 
spite of the fluctuations observed in this study, the overall median CD4 cell count (243.5 cells/l) 
was higher than previously observed trends in most sub-Saharan African countries (2,6). Of all the 
sub-Saharan African countries, Rwanda was the first to record median CD4 cell count greater than 
200 cells/l at ART initiation (7).  Additionally, the observed increase from 255 cells/l in 2013 
to 278 cells/l in 2015 in this study may be attributable to the pilot test of the ‘test and treat all’ 
strategy implemented in the south-south of Nigeria. The subsequent decrease in median CD4 cell 
in 2016 to 233 cells/l and increase to 244 cells/l in 2017 may have been influenced by other 
contextual, program or individual factors not addressed in this study. Also, our study found that 
while median CD4 cell count started increasing among women in 2017, it continued to decrease 
among men from 206cells/l in 2015 to 159 cells/l in 2017. This may imply that there is still a 
widening health disparity across gender in Nigeria which threatens the effectiveness of HIV care 
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and treatment scale-up in the nation. Future studies are needed to shed light on the effects of 
possibly modifiable factors that determine these outcomes and suggest strategies for gender-based 
interventions that promote earlier ART initiation among men. 
 
In multivariate models, our study found that patients aged 36-45 years and 46 years and above 
relative to those aged 15-25 years had about twice the odds of presenting with advanced HIV 
disease stage at ART initiation (Table 5). This is consistent with other studies in the sub-Saharan 
region (2,7,14). Even though sex was not significantly associated with presentation with advanced 
disease stage, other studies from sub-Saharan Africa have reported that older HIV positive males 
have been found more likely to present late to ART treatment with a lower median CD4 cell count 
and advanced disease stage and have a slower immune response compared to women (7,8,20–22). 
This suggests a persistent gap in the HIV care system to eliminate gender disparities in the 
timeliness of ART initiation across gender and age. Thus, more research is needed to elucidate 
drivers of the gap and identify opportunities to address these disparities.  
 
 The strength of this study includes a sex-specific analysis and the use of routinely collected patient 
data rather than data collected solely for the purpose of research only. Our study also reviews data 
over 5 years from 2013 to 2017, a period when the Nigerian national HIV guidelines where 
changed and our study location participated in the pilot test of the new guidelines. Our study has 
some limitations. First, our sample was limited to only patients enrolled into care at the target 
hospital, which may not represent the various types of HIV care settings across the country. 
Additionally, our study site collected data manually giving room for errors during data entry as 
well as data abstraction. Finally, about 6% of patients were excluded from the analysis due to 
missing data on parameters of interest for this study i.e. advanced disease stage thus, highlighting 
the importance of a thorough assessment of patients and an accurate documentation of laboratory 
and clinical findings.  
 
CONCLUSIONS 
In conclusion, the trends observed in our study points to a persistent and widening disparity in 
early diagnosis of HIV and treatment uptake between male and female HIV positive individuals 
in Nigeria. Consequently, additional research on the determinants of late ART initiation in the 
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‘treat all’ policy era with improved ART coverage is imperative. Age and gender specific 
interventions are needed to effectively identify, enroll and initiate ART treatment among HIV 
positive individuals in a timely manner. Without such efforts targeting mechanisms that mitigate 
early ART treatment initiation, the effectiveness of HIV treatment scale-up programs including its 
direct benefit to the individual and indirect benefits on population HIV incidence may be reduced 
over time.  
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Table 1: Patient characteristics 
 
 N Advanced HIV at ART Initiation P-value 
  Yes No  
Sex     
Male 338 (34.28) 89 (38.70) 249 (32.94) 0.11 
Female 648 (65.72) 141 (61.30) 507 (67.06)  
Age     
Median (IQR) 34 (29, 40)    
15-25 123 (12.47) 19 (8.26) 104 (13.74) 0.09 
26-35 442 (44.83) 101 (43.91) 341 (45.11)  
36-45 289 (29.31) 73 (31.74) 216 (28.57)  
≥46 132 (13.39) 37 (16.09) 95 (12.57)  
Year of ART Initiation    
2013 88 (9.06) 15 (6.67) 73 (9.79) 0.02 
2014 261 (26.88) 55 (24.44) 206 (27.61)  
2015 349 (35.94) 72 (32.00) 277 (37.13)  
2016 191 (19.67) 58 (25.78) 133 (17.83)  
2017 82 (8.44) 25 (11.11) 57 (7.64)  
Documented TB     
Yes 96 (9.85) 30 (13.45) 66 (8.78) 0.04 
No 879 (90.15) 193 (86.55) 686 (91.22)  
 
 
 
Figure 1: Median CD4 at ART initiation by Year of ART start 
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Figure 2: Advanced HIV Disease Stage by Year of ART Start 
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Table 2: Crude and Adjusted Odds Ratio of factors associated with Advanced HIV Disease Stage at ART initiation 
Characteristic N % Advanced 
HIV Disease 
Crude 
OR 
95% CI P- value Adjusted OR 95% CI P value 
Sex         
Male 89 26.33 1.29 0.95-1.74 0.11 1.17 0.84-1.62 0.35 
Female 141 21.76 Ref   Ref   
Age         
15-25 19 15.45 Ref   Ref   
26-35 101 22.85 1.62 0.95-2.77 0.08 1.59 0.91-2.77 0.11 
36-45 73 25.26 1.85 1.06-3.23 0.03 1.80 1.01-3.23 0.05 
46+ 37 28.03 2.13 1.15-3.96 0.02 2.10 1.10-3.99 0.02 
Year of ART 
Initiation 
        
2013 15 17.05 Ref   Ref   
2014 55 21.07 1.30 0.69-2.44 0.42 1.16 0.61-2.19 0.66 
2015 72 20.63 1.26 0.69-2.34 0.45 1.09 0.58-2.04 0.78 
2016 58 30.37 2.12 1.12-4.01 0.02 2.06 1.08-3.91 0.03 
2017 25 30.49 2.13 1.03-4.42 0.04 2.01 0.96-4.20 0.06 
Treat all era 622 68.89 Ref      
Pre -treat all era  349 31.11 0.76 0.55-1.04 0.09 - - - 
         
Documented 
Tuberculosis 
        
Yes 30 31.25 1.62 1.02-2.56 0.04 1.79 1.09-2.92 0.02 
No 193 21.96 Ref   Ref   
 
 
Bolded=P value ≤0.05 
Adjusted for age, sex and presence of TB 
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The Association between Baseline Clinical Characteristics and Long-term Antiretroviral 
Treatment Retention among HIV patients in Nigeria. 
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Abstract: 
 
Background: Long-term ART treatment retention among HIV patients is crucial in increasing 
immune response and ensuring patient attains viral suppression.  
Methods: Data was abstracted from clinic records of 1050 HIV positive adults aged 15 who 
initiated ART between 2013 and 2017 at a comprehensive clinic in Nigeria. All data was analyzed 
using STATA version 15.  
Results: The study population was 66.95% females and the median age was 34 years (inter 
quartile range [IQR], 29-40). Most participants started ART in 2014 (26.70%) and 2015 (35.24%). 
ART treatment retention was 71.39%, 79.50%, 74.01% and 62.67% at 6, 12, 24 and 36 months 
respectively. CD4 cell count <100 was inversely predictive of retention (AOR 0.55; 95% CI, 0.37-
0.82) while female gender (AOR, 2.00; 95% CI, 1.02 – 3.89), older age (AOR, 1.88; 95% CI, 1.01-
3.51), TB at start (AOR, 2.21; 95% CI, 1.02-4.75). and CD4 cell count 100-199 (AOR, 2.54; 95% 
CI, 1.04-6.20) were significantly associated with retention.  
Conclusion: Long-term HIV treatment retention in Nigeria like most other sub-Saharan nations 
continue to show a decrease in retention rates over duration in treatment. While it is important to 
address patient-related and structural barriers, multi-pronged care approaches are advocated to 
attain improved quality of life and sustainable viral suppression. Further research examining 
multiple factors that affect retention is recommended.  
 
Keywords: Gender, CD4 cell count, TB, HIV treatment, Long-term retention, Resource- limited 
setting 
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Background 
 
Antiretroviral therapy (ART) treatment retention is at the core for attaining improved patient health 
outcome among Human Immunodeficiency Virus (HIV) infected individuals (1,2). It is the 
sustained retention in treatment of HIV patients that ensures the benefits of ART are achieved by 
both individuals and public health (3). ART treatment retention provides an avenue for HIV 
patients to continue to receive ART medications as well as clinical management of any 
opportunistic infections (OIs) that may occur (3). Since ART treatment retention is defined as the 
a patient’s continued participation in HIV medical care including adherence to medication and 
clinic visits (3), attaining long-term care of HIV patients is imperative to mitigate the burden of 
HIV.  
 
Since 2006, Nigeria has continued to expand ART provision and care for people infected with HIV 
through partnerships with public and private stakeholders and the decentralization of treatment 
programs to tackle patient concerns regarding access to ART (1,2,4). With increased access to 
ART, treatment enrollment increased from 90,008 in 2006 to about 1,016,346 in 2018 showing a 
remarkable increase in ART treatment uptake in Nigeria (1,5,6). Notwithstanding the increased 
provision of ART treatment and related care to provide a panacea to individuals infected with HIV, 
there remain unresolved and daunting challenges in ensuring long-term retention of HIV infected 
individuals in treatment and care (7–9). This is especially so for HIV patients in low and medium-
income settings where people face more barriers like cost of transport to clinic and inadequate 
drug availability while trying to access ART (8–11). These barriers may contribute to lower 
retention rates and increased negative health consequences such as drug resistance, sub-optimal 
viral suppression and early mortality observed in these regions. Clinical baseline characteristics of 
patients have also been shown to impact retention rates over time. Data from an assessment of 
patient retention in ART care in the sub-Saharan Africa, showed rates of 85.6% at 12 months, 
79.3% at 24 months, 76% at 36 months and 73.1% at 48 months (10). These rates would mean that 
of 100 patients starting care, only about 30 patients would be retained at 48 months. Furthermore, 
a current systematic review of HIV cohorts showed that every third patient initiating ART was 
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classified as lost to follow-up within 3 years of care (12,13).  Consequently, these ART treatment 
retention rates imply a public health concern for the sub-Saharan Africa region.  
 
The high burden of HIV in Nigeria and her disproportionate prevalence rates continue to place her 
at the forefront of HIV research. Nigeria, a sub-Saharan country and the most populous country in 
West Africa has one of the highest numbers of people living with HIV (14). Data from Nigeria 
also show a decreasing ART retention rate over time (1,3). A study of HIV treatment programs 
across Nigeria reported retention rates ranged from 81% - 62% over a 4- year follow up period (2). 
These rates call into question the effectiveness of the programs offered to increase retention among 
HIV patients while raising the need to understand the possible interaction of multiple factors that 
impact ART treatment retention. Identifying correlates to retention in our study may assist in better 
HIV program intervention designs and resource allocation aimed at increasing ART treatment 
retention. Therefore, we aim to examine the long-term retention of HIV patients assessing ART at 
a comprehensive hospital in South-South Nigeria.  
 
Methods 
We conducted a retrospective cohort analysis of HIV infected individuals receiving ART treatment 
at a HIV clinic in a comprehensive hospital in south-south Nigeria from January 2013 to December 
2017.  
Data Source 
Patient information routinely collected at HIV treatment enrollment and during subsequent clinic 
visit was documented by clinic staff on standard forms used nationally. Trained data clerks 
manually abstracted 1,050 adult (aged ≥15 years) medical records from the hospital HIV clinic 
records and entered then into an electronic database. Data quality assessments were carried out 
every month to assess for accuracy and completeness until data collection was completed. Data 
was de-identified for analysis. 
Definitions and Outcomes 
ART treatment retention was defined as retention of patients receiving ART with continuous 
visits, i.e., no gap >90 days from next clinic appointment (12) in the first 6 months of care 
(defined as retained for 6 months) and in the following 6 months of care (defined as retained for 
12 months). 
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Data Analysis 
We examined characteristics of all study eligible patients initiating ART at the clinic. We then 
assessed the proportion of patients with retained in ART care at 6, 12, 24 and 36months. Bivariate 
analysis of each of the covariates and retention was assessed and reported. Multiple multivariable 
models with each treatment retention category were built and the covariates were added to 
determine any significant correlates to retention. We adjusted for age and gender. Odds ratios, 
adjusted odds ratios, 95% confidence interval and a p value were calculated. Significance was 
determined from a p value of < 0.05. Missing data were assumed as missing at random and were 
not included in the analysis. All statistical analysis was performed using Stata 15 (StataCorp. 2017. 
Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).  
Ethical Consideration 
IRB approval was obtained from the research approval committee of the study clinic, and The 
University of Texas Health Science Center at Houston. 
 
Results 
 
A total of 1050 patients were eligible for this study. Males accounted for 33.05% while females 
were 66.95% of the study population (Table 1). The median age was 34 years (inter quartile range 
[IQR], 29-40). Most of the participants initiated ART in 2014 (26.70%) and 2015 (35.24%). Table 
1 also shows retention was 71.39% at 6 months, 79.50% at 12 months, 74.01% at 24 months and 
62.67% at 36 months. There was no significant difference in retention at 6, 12, 24 and 36 months 
across gender or year of treatment entry. Table 1 shows the median CD4 cell count at baseline was 
243.5 cells/l. While females presented with higher median CD4 cell counts at baseline (246 
cells/l), males presented with a lower median of 229.5 cells/l at baseline. Females had a slightly 
higher proportion of documented tuberculosis compared to males (10% versus 9%) at baseline. 
Females were also more likely to start ART treatment on the same day they were enrolled into care 
compared to the males (71.99 versus 67.66%).  
 
In bivariate analyses shown in Table 2, CD4 cell count <100 compared to CD4 cell count ≥350 
was a significant predictor of retention at 6 and 24 months (crude odds ratio [COR], 0.53; 95% CI, 
0.36-0.78 and COR, 0.44; 95% CI, 0.25-0.79 respectively) such that those who have <100 have 
lower odds of been retained in treatment at 6 and 24 months, same day ART start compared to 
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those who did not start ART on same day of treatment enrollment was predictive of retention at 6 
months as well, a positive TB status at baseline compared to a negative TB status was also 
predictive of retention at 12 months (COR, 2.22; 95% CI, 1.04-4.74). The association between 
same day ART start and retention at 12 months was not significant in multivariate analyses while 
all other significant bivariate associations remained significant in multivariate analyses (a) CD4 
cell count <100 compared to CD4 cell count ≥350 at 6 and 24 months (adjusted odds ratio [AOR] 
0.55; 95% CI, 0.37-0.82; AOR, 0.46; 95% CI, 0.25-0.84) (b) a positive TB status at baseline 
compared to a negative TB status (AOR, 2.21; 95% CI, 1.02-4.75). Also, CD4 cell count of 100-
199 compared to CD4 cell count ≥350 (AOR, 2.54; 95% CI, 1.04-6.20) and female gender 
compared to male (AOR, 2.00; 95% CI, 1.02 – 3.89) was significantly associated with retention at 
36 months and age group 36-45 compared to age 46+ (AOR, 1.88; 95% CI, 1.01-3.51) was 
predictive of 12 months retention as shown in Table 3. 
 
Discussion 
 
This study examined retention in ART treatment over a 3-year period among HIV patients 
receiving treatment at a comprehensive hospital in Nigeria. The findings in this study are similar 
to retention rates reported in previous studies in Nigeria and other sub-Saharan countries (2,9,10). 
A systematic review of patient retention in sub-Saharan Africa between 2002-2009 showed a 
64.6% retention at 36months after adjusting for variable follow-up time in a sensitivity analysis 
(8). Previous studies reviewing data across Nigerian ART service programs also found similar 
results of decreasing retention rates over time (1,2). This continued decrease in retention rates over 
time has been attributed to reasons such as loss to follow up, death, treatment transfers, religious 
and economic factors as well as intentional discontinuation of treatment due to improved health 
(1,16). Specifically, this study observed that patients who presented with advanced HIV disease 
stage (CD4 cell count <100) were less likely to be retained in treatment at 6 and 24 months follow 
up. This finding collaborates reports from previous studies in Nigeria that suggest lower retention 
among patients presenting with CD4 cell counts <100 at ART initiation (2,17,18).  Research has 
also suggested patients with advanced HIV disease stage have lower odds of immune recovery and 
may contribute a high proportion of early mortality thus lower observed retention rates (19,20).  
The early mortality rates may also explain why we did not observe any significant association 
between CD4 cell count <100 and retention at 36 months. On the other hand, our study observed 
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a significant association between documented positive TB status at baseline with retention at 12 
months. This may be due to the National Tuberculosis Control Program (NTP) implemented in 
Nigeria since 2007 with extra program retention strategies provided to TB patients to ensure 
treatment adherence and disease containment (21). In a study where patients were traced to their 
homes, patients and/or family members were reported to express excitement at the home visits and 
made decisions to come in to clinic at the next appointment (22). Also, researchers found patient 
engagement through extra in person follow-ups and via mobile device, text messages, 
neighborhood peer counselors, home visits, phone calls and contact tracking were effective in 
maintaining treatment retention (23–25). This implies that targeted and consistent patient follow-
up may boost treatment retention. 
 
Like previous studies, our study found females had higher odds of been retained in long-term 
treatment (2,18). In addition, our study found older age (36-45 years) was predictive of treatment 
retention at 12 months. While studies have shown gender-differences in health-seeking behaviors, 
PMTCT programs in sub-Saharan Africa which target women have been shown to increase 
retention in care among women (26,27). Yet, there are still little or no programs directly targeted 
at increasing ART treatment uptake and retention among males. Culturally- sensitive programs are 
needed to minimize the long-standing disparity in treatment uptake and retention across gender in 
Nigeria. Likewise, age-appropriate programs are necessary to ensure adequate service uptake and 
long-term retention across all age groups.  
 
The strength of this study includes the review of routinely collected data over a period of time. 
However, our study was limited due to difficulties rising from incomplete data. Some initial 
variables of interest that may be associated with the outcome variable could not be examined due 
to incomplete data. We recommend further studies that review multiple factors associated with 
retention and advocate for advanced health care data management systems in Nigeria to improve 
study results that drive HIV policies and programs. 
 
Conclusions 
Long-term ART retention among HIV patients is vital to restoring health and improving quality 
of life by achieving viral suppression. Achieving viral suppression means patient viral load is 
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undetectable hence untransmittable. This study demonstrates that long-term ART retention is still 
a challenge for the Nigerian HIV care program. While differentiated and multi-pronged care 
approaches are advocated, structural and patient-related barriers should be addressed to ensure that 
ART retention strategies are effective and more importantly sustainable.  
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Table 1: Patient characteristics at ART Treatment Start             
Variable N (%) Retention at 6 
months 
Retention 
at 12 
months 
Retention 
at 24 
months 
Retention 
at 36 
months 
 1050 (100%) 721 (71.39) 539 (79.50) 336 (74.01) 141 (62.67) 
Sex      
Male 347 (33.05) 237 (71.17) 174 (76.99) 106 (73.61) 36 (55.38) 
Female 703 (66.95) 484 (71.49) 365 (80.75) 230 (74.19) 105 (65.62) 
Age, y      
Median (IQR) 34 (29, 40)     
15-25 136 (12.95) 91 (71.65) 65 (76.47) 44 (80.00) 20 (62.50) 
26-35 477 (45.43) 313 (68.19) 232 (78.91) 142 (71.00) 59 (61.46) 
36-45 301 (28.67) 220 (75.34) 175 (83.33) 111 (77.08) 46 (63.89) 
≥46 136 (12.95) 97 (73.48) 67 (75.28) 39 (70.91) 16 (64.00) 
Year of ART Treatment start     
2013 93 (9.03) 71 (76.34) 55 (77.46) 38 (70.37) 26 (70.27) 
2014 275 (26.70) 202 (73.72) 168 (83.58) 141 (84.43) 114 (82.01) 
2015 363 (35.24) 255 (71.43) 208 (82.21) 156 (75.36) - 
2016 198 (19.22) 139 (70.92) 102 (73.38) - - 
2017 101 (9.80) 52 (59.77) - - - 
CD4 count cell/l     
Median (IOR) 243.5 (107-
405) 
    
<100 230 (23.33) 141 (63.23) 98 (74.81) 47 (57.32) 24 (66.67) 
100-199 173 (17.55) 119 (71.26) 91 (79.13) 59 (77.63) 31 (70.45) 
200-349 269 (27.28) 207 (78.71) 164 (82.00) 121 (82.88) 51 (60.71) 
≥350 314 (31.85) 230 (76.41) 175 (81.40) 106 (75.18) 33 (55.93) 
Documented Tuberculosis     
Yes 98 (9.50) 74 (77.89) 65 (12.08) 52 (15.48) 17 (12.06) 
No 934 (90.50) 643 (71.05) 473 (87.92) 284 (84.52) 124 (87.94) 
Same Day ART Start     
Yes 719 (70.56) 495 (68.85) 368 (68.40) 222 (66.07) 97 (68.79) 
No 300 (29.44) 224 (31.15) 170 (31.60) 114 (33.93) 44 (31.21) 
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Table 2: Bivariate association between variables of interest and treatment retention at 6, 12, 24 
and 36 months 
 (1) (2) (3) (4) 
VARIABLES Crude OR 
(CI) 
Crude OR 
(CI) 
Crude OR 
(CI) 
Crude OR 
(CI) 
Sex     
Male Ref Ref Ref        Ref 
Female 1.02 (0.76-1.38) 1.25 (0.85 - 1.85) 1.03(0.65-1.62) 1.54 (0.85 - 2.77) 
     
Age     
15-25 0.91(0.53-1.57) 1.07 (0.53-2.14) 1.64 (0.68-3.96) 0.94(0.32-2.78) 
26-35 0.77 (0.50-1.19) 1.23 (0.70 - 2.15) 1.00 (0.53-1.94) 0.90 (0.36-2.24) 
36-45 1.10 (0.69-1.76) 1.64 (0.90- 3.00) 1.38 (0.69-2.78) 1.00 (0.39-2.57) 
46+ Ref Ref Ref Ref 
    
CD4 at ART 
Start 
    
<100 0.53 (0.36-0.78) 0.68 (0.40-1.15) 0.44 (0.25-0.79) 1.58 (0.83-5.85) 
100-199 0.77 (0.50-1.17) 0.87 (0.49 - 1.53) 1.15 (0.59-2.22) 1.88 (1.14-8.11) 
200-349 1.14 (0.77-1.70) 0.81 (0.63 - 1.71)  1.60 (0.90-2.84) 1.22 (1.03-4.91)  
≥350 Ref Ref Ref Ref 
     
Documented 
TB 
    
Yes 1.44 (0.87-2.38) 2.22 (1.04-4.74) 1.60 (0.82-3.12) 0.69 (0.32-1.47) 
No Ref Ref Ref Ref 
     
Same day ART 
Start 
    
Yes 0.72 (0.53-0.98) 0.91 (0.60-1.36) 0.73 (0.46-1.17) 0.88 (0.49-1.59) 
No Ref Ref Ref Ref 
 
Retention at 6 months (1), Retention at 12 months (2), Retention at 24 months (3) and Retention 
at 36 months (4). Bolded values show P value ≤0.05 
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Table 3: Multivariate association between variables of interest and treatment retention at 6, 12, 
24 and 36 months 
 (1) (2) (3) (4) 
VARIABLES Adjusted OR 
(CI) 
Adjusted OR 
(CI) 
Adjusted OR 
(CI) 
Adjusted OR 
(CI) 
Sex     
Male Ref Ref          Ref        Ref 
Female 1.16 (0.84-1.60) 1.32 (0.87-2.01) 1.12 (0.68-1.85) 2.00 (1.02 – 3.89) 
     
Age     
15-25 0.87(0.47-1.60) 1.00 (0.47-2.10) 2.11 (0.78-5.69) 0.63 (0.20-2.04) 
26-35 0.75 (0.47-1.21) 1.18 (0.66-2.11) 1.02 (0.50-2.06) 0.62 (0.23-1.67) 
36-45 1.04 (0.63-1.71) 1.88 (1.01-3.51) 1.45 (0.70-3.00) 0.80 (0.30-2.15) 
46+ Ref Ref Ref Ref 
     
CD4 at ART 
Start 
    
<100 0.55 (0.37-0.82) 0.62 (0.36-1.06) 0.46 (0.25-0.84) 1.71 (0.70-4.17) 
100-199 0.75 (0.49-1.16) 0.72 (0.40-1.30) 1.15 (0.57-2.29) 2.54 (1.04-6.20) 
200-349 1.15 (0.77-1.72) 0.99 (0.59-1.64)  1.70 (0.95-3.07) 1.39 (0.69-2.80)  
≥350 Ref Ref Ref Ref 
     
Documented 
TB 
    
Yes 1.48 (0.59-2.59) 2.21 (1.02-4.75) 1.67 (0.82-3.41) 0.53 (0.23-1.21) 
No Ref Ref Ref Ref 
     
Same day ART 
Start 
    
Yes 0.87 (0.63-1.21) 0.99 (0.65-1.51) 0.79 (0.49-1.28) 0.96 (0.52-1.78) 
No Ref Ref Ref Ref 
     
 
Retention at 6 months (1), Retention at 12 months (2), Retention at 24 months (3) and Retention 
at 36 months (4). 
Bolded values show P value ≤0.05 
Adjusted for covariates  
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JOURNAL ARTICLE 3 
Food Security Levels and Treatment Support Programs are Associated with ART 
Adherence among HIV patients in a semi-urban Uganda setting. 
 
Journal: BMC AIDS RESEARCH AND THERAPY 
 
Abstract: 
Background: Antiretroviral therapy (ART) adherence is vital in minimizing virologic failure, 
progression to AIDS and mortality among people living with HIV.  ART adherence decreases the 
likelihood of HIV transmission. However, food insecuirty increases susceptibility to HIV infection 
and worsens poor clinical outcomes among HIV patients. 
Methods: A one-time structured cross-sectional survey conducted between November 2017 and 
February 2018 among HIV patients aged 18 years in Eastern Uganda. Food security level was 
measured using the Household Food Insecurity Access Scale (HFIAS) and was categorized into 
two groups- food secure and food insecure. Good adherence level is set at >90% from self- reported 
ART adherence for a 4 week recall from the time of data collection. All data was analyzed using 
STATA version 15.  
Results: Of the 545 participants, over two-thirds of the participants were females (77%) and 
median age was 35 years (inter quartile range [IQR], 29-43). Overall food security level in Uganda 
was 65.5%. HIV positive males reported higher food security levels compared to females (77.60% 
vs 61.90). Food security (AOR, 1.76; 95% CI, 1.03-3.01), income (AOR 2.69; 95% CI, 1.14-6.34) 
and nutrition counseling (AOR, 1.99; 95% CI, 1.12-3.54) were significantly associated with good 
adherence.  
Conclusion: Male-led households were found to be more food secure compared to female-led 
households. Promoting food security and treatment support programs may be effective in 
advancing HIV care in the sub-Saharan Africa. Additional research aimed at understanding the 
interactions between treatment support programs, food security levels and ART adherence are 
needed. 
 
Keywords: Gender, Food security, Treatment support, Food support, ART adherence, Resource-
limited setting 
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Introduction 
Antiretroviral therapy (ART) is crucial for the optimal health outcome of individuals infected with 
Human Immuno-deficiency Virus (HIV) (1–3). Adequate adherence to ART is important in 
minimizing virologic failure, progression to AIDS and mortality among people living with HIV 
(1,2,4). Adequate ART adherence means sticking to a firm HIV regimen by taking medications 
daily and as prescribed (5,6). Adherence to ART also decreases the likelihood of HIV transmission, 
emphasizing the importance of adherence for secondary prevention (2). Despite the established 
importance of ART, a meta-analysis found that the proportion of patients attaining optimal ART 
adherence was 77% in sub-Saharan Africa (2,7). Therefore, there is a need to continue to examine 
the determinants of ART adherence in this region particularly as research suggests ART adherence 
levels of less than or equal to 80% of medications taken on time may have a treatment failue of 
80% (1). 
 
Data from studies in low-income settings suggest a growing knowledge of the association between 
food insecurity and poor ART adherence among HIV patients (3,8–10). Food insecurity has been 
defined as ‘the state when people do not have physcial, social and economic access to sufficient 
safe and nutritious foods that meet their dietary needs and food preferences for an active and 
healthy life’ (11). Studies have also identified a vicious cycle between food insecurity and HIV 
(2,3,9,12). A meta-analysis reviewed the drivers of food insecurity and found poverty, prevalence 
of HIV/AIDS, lack of educational and employment status were key determinants of household 
food insecurity (13). Moreover, data show that food consumption often dropped by about 40% in 
households affected by HIV/AIDS (14,15). This was either due to reduced prodcutivity and income 
or increased health care needs (14). Food insecuirty not only increases susceptibility to HIV 
infection but also worsens poor clinical outcomes among HIV patients (9). Weiser et al found that 
HIV patients who reported limited access to food were more likely not to be ART adherent; thereby 
resulting in health decline and greater difficulty in accessing food (16). Qualitative data from 
resource- poor settings also identified that food insecurity is a key reason for ART non-adherence 
(16–19) due to factors such as decreased income, increased hunger and competing subsistence 
needs and they could consequently led to poor adherence (3,20).  
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With current recommendations from policymakers for a more comprehensive approach to HIV 
care, intervention programs are increasingly adding several components to HIV care such as  food 
assistance, livelihood support, adherence and nutritional counseling as well as support groups 
among others to drive ART adherence and treatment retention. Early data suggests counseling 
services and food assistance may increase food security levels, clinic visits, ART adherence, 
retention in care and survival of HIV patients (21–24). However, the effect of such support services 
on ART adherence is still not very clear in this study setting. While some studies show food 
assistance alone was significant in increasing ART adherence, others suggest food assistance with 
other support programs were more effective (2). As more resources are directed towards ART 
treatment support interventions,  it is imperative to examine if these support services are effective 
in improving ART adherence in resource-constraint settings. 
 
Uganda, a resource-constraint nation in sub-Saharan Africa has a high prevalence of both HIV and 
food insecurity (16,25). Current data show a national HIV prevalence of 5.9% with about 1.2 
million people living with HIV in Uganda (26). Annually in Uganda, 12% of the people aged 15 
to 49 years old die of AIDS (15,20). This decrease in the productive age group has contributed to 
increased food insecurity among HIV affected households due to reduced income and competing 
needs (15). According to a Ugandan study on HIV infected individuals, 22% of the households 
reported that sometimes or often all household members had no food to eat for an entire day 
(15,16). Around 62% of the study participants also reported that sometimes or often all household 
members had to skip meals and 95% reported that household members sometimes or often had to 
eat less preferred foods (15,16). Another study in Uganda found that consuming only one meal per 
day and being dependent on caregivers for food were risk factors for poor ART adherence (16,27). 
Likewise, other studies found that HIV patients who are food insecure are less likely to adhere to 
treatment and may experience treatment interruptions leading to treatment drop out (15,16,20,25). 
Besides, existing gender-based food norms in Uganda also affects the occurrence of household 
food insecurity among male- and female- led households (19,28).  
 
Factors contributing to the association between food insecurity and ART adherence in Uganda 
may be aggravated or lessened by patient socio-demographics as well as socio-cultural norms. 
Also, the different indigenous ethnic groups in Uganda are defined by their traditional food 
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preferences to a certain extent (29). Educational level, family income and assets, number of 
dependents and martial status have also been found to contribute to household food insecurity (29). 
Study participants who were single or widowed and/or had more than four children were more 
likely to be food insecure and non-adherent to ART (16,30). While socio-cultural norms will not 
be explored in this study, it is important to mention that gender-based food taboos, cultural norms 
and myths in Uganda may influence household food insecurity levels (28,29). A qualitative study 
with 133 participants in Uganda found that all women, regardless of their physiological status 
(non-pregnant or pregnant or lactating), were restricted from eating various animal-based foods 
and some plant-based foods as well (28). In most cultures with food taboos, women and children 
are generally the most affected (29).  
 
Since ART medication requires lifelong adherence, reviewing household food security levels is 
fundamental to the four core pillars of a holistic response in HIV prevention, care, treatment and 
mitigation. Given that food insecurity is endemic in sub-Saharan Africa,  it is important to 
determine the degree of the association between food security levels and ART adherence in areas 
such as Uganda where other socio-demograhic and cultural factors may contribute to the effects 
of food security on ART adherence (3,20) and identify effective interventions that could improve 
patient health outcomes. Given the scope of this study, we plan to review socio-demographic 
characteristics and food security levels of patients receiving ART care in Uganda and hypothesize 
that HIV patients who are food secure have higher odds of better ART adherence. 
 
Methods 
Data Source: 
We conducted a cross-sectional study involving HIV patients receiving ART at two level 3 health 
care centers in semi-urban communities in Eastern Uganda. Clinics in the region participate in 
various funded food assistance program and provide care to over 1000 HIV patients annually. Data 
were collected from any consenting male and female HIV patients aged 18 years old and above 
who attended clinic on a given data collection day using a one-time structured survey between 
November 2017 and February 2018. Data obtained included patient socio-demographic 
characteristics, HIV- related health services and care practices, ART treatment adherence, 
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nutritional exposures and food security assessments. At the end of the study period, 545 
questionnaires were completed with a 90% consent rate. 
 
 
Definitions and Outcomes 
Good adherence level is set at >90% from self- reported ART adherence for a 4 week recall from 
the time of data collection (5,9). To measure the primary dependent variable (self-reported 
adherence), a validated Visual Analogue Scale assessed adherence over the past month (31). This 
tool consists of questions measuring adherence over a period of time (past 30 days) and recall 
questions to reduce situations of potential bias in missed- ART doses. 
  
Food security level is categorized into two groups- food secure and food insecure. To measure the 
primary independent variable (household food security), the Household Food Insecurity Access 
Scale (HFIAS) was utilized. HFIAS has nine yes/no questions (e.g. Did you worry that your 
household would not have enough food? Were you or any household member not able to eat the 
kinds of foods you preferred because of a lack of resources?) (9,32).  The HFIAS score is computed 
to categorize patients into food insecure and food secure groups using a distribution- based 
category (33,34). This tool has been adapted to fit rural and urban study settings and it has been 
broadly used in different cultural settings (32).  
 
Data Analysis 
We examined socio-demographic characteristics of all consenting and eligible HIV infected 
individuals (male and female) aged 18 years and above participating in the study. We then assessed 
the level of food security among study participants using the nine item- Household Food Insecurity 
Access Scale (HFIAS). The scale has a maximum score of 27. Study participants with higher 
scores are considered food insecure.  Chi square tests were conducted to assess the association 
between covariates and food security levels. Bivariate analysis of ART adherence and the main 
independent variable as well as each of the covariate was assessed and reported. All variables were 
added to a multivariable model to determine any significant correlates to ART adherence while 
adjusting for age, gender and income. Odds ratios, adjusted odds ratios, 95% confidence interval 
and a p value was calculated. Significance was set from a p value of < 0.05.  Missing data were 
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assumed as missing at random and were not included in the analysis. All statistical analysis was 
performed using Stata 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, 
TX: StataCorp LLC).  
 
Ethical Consideration: 
Initial data collection IRB approval for this study was obtained from the research approval 
committee of the health center administration in Jinja district in Uganda. Another IRB was 
obtained from The University of Texas Health Science Center at Houston for the use of de-
identified secondary data. 
 
Results 
 
Characteristics of study participants 
The socio-demographic characteristics of 545 adults aged 18 and above who participated in this 
study are presented in Table 1. Over two-thirds of the participants were females (77%). The median 
age was 35 years (inter quartile range [IQR], 29-43); about half of the participants had a primary 
school education (47%) and four or more children (46%). Most (78%) of the participants earned 
less than 500,000 Ugandan shillings per month and 54% were either married or cohabiting with a 
partner. 
 
Proportion of participants that received support services after HIV Diagnosis 
The proportion of participants that received different kinds of support services from the treatment 
clinics after HIV diagnosis are reported in Table 2. Only few study participants reported receiving 
adherence support/counseling (8%), adherence support group (2%) and food support or package 
(3%). However, about two-thirds of the participants reported that they received nutrition 
counseling (76%) after HIV diagnosis.  
 
Food security assessment of participants 
The nine-item Household Food Insecurity Assessment Scale (HFIAS) was used to assess the food 
security level of the study participants. When asked to recall assessment questions for the past 
month, about one-third of the study participants reported they worried their household would not 
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have enough food, were not able to eat the kinds of foods they preferred because of lack of 
resources, had to eat a limited variety of foods due to lack of resources, ate some foods they did 
not really want to eat because of lack of resources to obtain other food types, ate a smaller meal 
than needed because there was not enough food and ate fewer meals in a day because there was 
not enough food. For the questions ‘was there ever no food to eat of any kind in your household 
because of lack of resources to get food’ and ‘did you or any household member go to sleep at 
night hungry because there was not enough food’, about 20% of participants gave a positive 
response. About 16% said they or some household member went the whole day and night without 
eating on some days in the four weeks recall period. Overall, 65.5% were classified as food secure 
in this population.  
 
Factors associated with Food Security Level 
Chi-square test was used to determine the association between socio-demographic characteristics 
and food security levels (Table 1).  Gender, education and income were significantly associated 
with food security levels while age, number of children and head of household were not 
significantly associated with food security level. 
 
Factors associated with ART Adherence 
In bivariate and multivariable analyses, income and food security levels were significantly 
associated with ART adherence (Table 3). Participants who earned ≥500, 000 Ugandan shillings 
per month compared to those who earned <500,000 showed higher odds of adhering to their ART 
(crude odds ratio [COR], 2.76; 95% CI, 1.23-6.19; adjusted odds ratio [AOR], 2.69; 95% CI, 1.14-
6.34). Participants who were food secure also showed higher odds of ART adherence compared 
with the food insecure group (COR, 1.77; 95% CI, 1.06-2.96; AOR, 1.76; 95% CI, 1.03-3.01). In 
the multivariable model alone, higher odds of ART adherence was observed among study 
participants who received nutrition counseling after HIV diagnosis compared to those who did not 
report receiving nutrition counseling (AOR, 1.99; 95% CI, 1.12-3.54).  
 
Discussion 
Our study observed a high proportion of the participants were food secure (65.5%). The proportion 
of food secure participants observed in this study is higher than those reported in a previous study 
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in Uganda (21.5%) among HIV positive individuals, yet lower than the current FAO projection of 
food secure Ugandans (89%). This variation may be due to the reported disproportionate spread 
of food security levels across the northern and southern parts of the country. The northern part of 
Uganda is reported to experience low rainfall and drought, which results in lower agricultural 
produce leading to higher levels of food insecurity. Since, our study was conducted in the eastern 
part of Uganda, the study participants may not have experienced harsh environmental changes that 
affect access to food.  
 
 Gender, level of education and monthly income were significantly associated with the food 
security levels of the participants. This finding is consistent with previous literature that found that 
educational levels and monthly income as well as gender of the head of the family were associated 
with food security levels (34,35). Gender disparities in food security levels have been reported 
across various sub-Saharan settings (16,29,35,36). Male led-households were more likely to be 
food secure compared to female led-households.  This may be because women, especially those 
who are single or widowed were poorer yet solely responsible for feeding family members (16,35). 
Also, participants with higher levels of education and income were more likely to be food secure 
compared to those with lower educational levels and income. Data shows even HIV infected 
individuals with higher educational status are more likely to get better paying jobs thus higher 
income and earnings. People who report higher earnings are more likely to satisfy their dietary 
needs and maintain adequate food security levels (34). On the other hand, HIV infected individuals 
may experience loss of earnings and face economic challenges due to more frequent sick days. 
Thus, if there are no support measures in place, HIV can very quickly turn food security levels 
negative through limited ability to work and ultimately worse health outcomes. 
 
Our study also observed a high proportion of the participants reported optimal ART adherence 
greater than the proportion of patients attaining optimal ART adherence in sub-Saharan Africa 
(87.34% vs 77%). This may be explained by the self-reported measure of ART adherence we used. 
Even though VAS is a validated tool, study participants may have reported ART adherence in a 
manner they perceived as more favorable. However, in a qualitative study conducted in Uganda, 
results showed high motivation for ART adherence even when other obstacles existed (16) 
suggesting the potential for increase in ART adherence within suitable conditions. 
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In multivariate analysis, our study showed a significant association between food security levels 
and ART adherence. This association remained significant after adjusting for income, education 
and gender. This finding is consistent with previous literature establishing a link between food 
security and good ART adherence (2,9,30). Previous studies found better food security levels 
minimized ART treatment interruptions and improved ART adherence (21,22). In a prospective 
cohort study conducted in Haiti, HIV patients who were provided food assistance showed 
improved body mass index, improved food security level and improved ART adherence (22).  
Furthermore, findings in this study showed nutrition counseling was also significantly associated 
with good ART adherence after adjusting for covariates. This is also consistent with a literature 
review that found nutrition counseling had an enabling effect on ART adherence and improved 
adherence and/or treatment completion (37).  Besides, policymakers recommend the use of 
nutrition assessment, counseling and support (NACS) intervention approach in strengthening the 
care continuum of HIV infected individuals (8,37,38). Even though food support, adherence 
support group and adherence counseling were not significantly associated with ART adherence in 
this study, a combination of various support programs have been shown to improve ART 
adherence and retention across various sub-Saharan countries. While the low uptake of these 
services may explain the non-significance observed in this study, it may also suggest a gap in the 
access to recommended comprehensive care package offered to HIV patients. Thus, the need for 
further research to evaluate the feasibility of service uptake in various service settings with the 
goal to improve food security and treatment adherence. Furthermore, since ART is a life-long 
treatment, minimizing the adverse and likely bidirectional association between food insecurity and 
ART adherence is imperative in achieving the optimal benefits of ART among HIV patients and 
the populace.  
 
There were several limitations to our study due to the cross-sectional study design. The study was 
conducted at semi-urban treatment clinics and participants were recruited among patients who 
attended clinic on data collection days and consented to participate in the study. This may limit 
the generalizability of the study findings to other populations. Social desirability bias and recall 
bias are potential limitations that may have also occurred in this study. Yet, the finding that food 
security was significantly associated with ART adherence in crude and adjusted analysis suggests 
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a strong relationship as observed in previous studies as well. Further research with varying study 
designs are required to determine the scope of the relationship between treatment support programs 
and ART adherence. 
 
Conclusion 
This study demonstrates that various factors drive food security levels among HIV-infected 
individuals in semi-urban Uganda. Findings also suggest a difference in male and female-led 
household food security levels. Our study points to a relationship between food security levels, 
nutrition counseling and ART adherence.  Additional research to fully understand the interactions 
between food security levels and food support programs; adherence support programs and ART 
adherence are needed. Also, program evaluations that review the long- term efficacy of support 
programs for ART treatment adherence are essential to developing strategies to minimize the 
adverse effects of poor food security levels on the overall health outcomes of HIV patients. 
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Table 1: Socio-demographic characteristics of study participants by Food Security and ART 
Adherence 
 
Characteristic N (%) Food Secure Good ART 
Adherence  
Gender    
Male 125 (22.94) 97 (77.60)* 112 (23.53) 
Female 420 (77.06) 260 (61.90) 364 (76.47) 
Age     
Median (IOR) 35 (29-43)   
18-29 138 (25.32) 98 (71.01) 118 (24.79) 
30-39 220 (40.37) 141 (64.09) 195 (40.97) 
40-49 128 (23.49) 81 (63.28) 112 (23.53) 
50+ 59 (10.83) 37 (62.71) 51 (10.71) 
Education    
No School 103 (18.90) 60 (58.25) 86 (18.07) 
Primary 257 (47.16) 156 (60.70) 228 (47.90) 
Secondary and 
Higher 
185 (33.94) 141 (76.22)* 162 (34.03) 
Number of children    
0-3 295 (54.13) 200 (67.80) 254 (53.36) 
4+ 250 (45.87) 157 (62.80) 222 (46.64) 
Income 
(Uganda shillings) 
   
 <500,000  425 (77.98) 259 (60.94) 425 (77.98)* 
≥500, 000  120 (22.02) 98 (81.67)* 120 (22.02) 
Head of Household    
One 252 (46.24) 160 (63.49) 217 (45.59) 
Two 293 (53.76) 197 (67.24) 259 (54.41) 
    
*=p<0.05 
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Table 2: Support Services offered after HIV Diagnosis 
Support Services N (%) Good ART 
Adherence  
Adherence support/ 
counseling  
  
Yes  43 (7.89) 39 (8.19) 
No 502 (92.11) 437 (91.81) 
Nutrition counseling   
Yes 412 (75.60) 366 (76.89)* 
No 133 (24.40) 110 (23.11) 
Adherence support group   
Yes 11 (2.02) 10 (2.10) 
No 533 (97.98) 466 (97.90) 
Food support/package   
Yes 15 (2.75) 13 (2.73) 
No 530 (97.25) 463 (97.27) 
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Table 3: Factors associated with ART adherence 
Variables Good ART Adherence (>90) 
Crude OR (95% CI) **Adjusted OR (95% CI) 
Gender   
Male 1.33 (0.70-2.51) 1.09 (0.55-2.16) 
Female Ref Ref 
Age   
18-29 Ref Ref 
30-39 1.32 (0.70-2.48) 1.21 (0.62-2.39) 
40-49 1.19 (0.59-2.40) 1.07 (0.47-2.42) 
50+ 1.08 (0.45-2.61) 0.99 (0.37-2.65) 
Education   
No school Ref Ref 
Primary 1.55 (0.81-2.97) 1.60 (0.82-3.15) 
Secondary and 
Higher 
1.39 (0.71-2.75) 1.23 (0.58-2.59) 
Number of Children   
0-3 Ref Ref 
4+ 1.28 (0.78-2.14) 1.31 (0.73-2.37) 
Income   
<500,000 Ref Ref 
≥500, 000 2.76 (1.23-6.19) 2.69 (1.14-6.34) 
Head of Household   
One Ref Ref 
Two 1.23 (0.74-2.04) 1.02 (0.60-1.74) 
Food security    
Food secure 1.77 (1.06-2.96) 1.76 (1.03-3.01) 
Food insecure Ref Ref 
Adherence support/ 
counseling  
  
Yes  1.45 (0.50-4.19) 1.68 (0.56-5.07) 
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No Ref Ref 
Nutrition counseling   
Yes 1.66 (0.97-2.87) 1.99 (1.12-3.54) 
No Ref Ref 
Adherence support 
group 
  
Yes 1.46 (0.18-11.58) 1.42 (0.16-12.43) 
No Ref Ref 
Food 
support/package           
  
Yes 0.94 (0.21-4.26) 0.76 (0.15-3.72) 
No Ref Ref 
 
Bolded if P value= ≤0.05 
**Adjusted for confounders 
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